How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

229 results for

Microdermabrasion

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

141. Onabotulinum Toxin Type A and Abobotulinum Toxin Type A Crow's Feet Rhytid Study

to during the current study. Non-ablative treatments in the lateral orbital region for skin dyschromias (e.g. Intense Pulsed Light, light-emitting diodes) at any time during the current study. Non-ablative dermal treatment in the lateral orbital area for skin tightening (e.g. radiofrequency treatments at any time preceding the current study or planned to have this done during the current study. Retinoid, microdermabrasion, or prescription-level glycolic acid treatments to the lateral orbital area within

2012 Clinical Trials

142. Safety Study of Plasma Treatment System to Treat Back Acne

on the skin of the back such as chemical or laser peel, microdermabrasion, photodynamic therapy) within the past 2 weeks or during the study. History or evidence of other skin conditions or diseases that may require concurrent therapy or may interfere with the evaluation of the study medication Any significant medical conditions that could confound the interpretation of the study results. History of/or current skin cancer cancer Use of tanning booths, sun lamps within the past 2 weeks or during the study

2012 Clinical Trials

143. A Phase 2 Dose Escalating Study to Evaluate the Safety and Efficacy of CB-03-01 Cream in Subjects With Facial Acne Vulgaris

, tretinoin, within four weeks of the initiation of treatment. Light treatments, microdermabrasion or chemical peels within eight weeks of the initiation of treatment. Subject has used the following systemic anti-acne medications: Corticosteroids (including intramuscular and intralesional injections) within four weeks of the initiation of treatment. Inhaled, intranasal or ocular corticosteroids are allowed if use is stable (stable use is defined as dose and frequency unchanged for at least four weeks

2012 Clinical Trials

144. Pilot Study to Evaluate Tea Tree Oil Gel for Facial Acne

weeks Use of systemic retinoids within the past 6 months Procedures on the face such as peels, laser therapy or microdermabrasion within the past 4 weeks Women who are pregnant or breastfeeding Women of childbearing potential not using a reliable contraceptive method. Participants taking oral contraceptives must have been taking their current contraceptive for the previous 3 months and must agree to continue with it until study completion. Participation in another clinical trial during the last 12

2012 Clinical Trials

145. Comparison of Escalating Doses of IncobotulinumtoxinA (Xeomin®) in the Treatment of Glabellar Rhytids

) at any time during the current study. Non-ablative dermal treatment in the glabellar area for skin tightening (e.g. radiofrequency treatments at any time preceding the current study or plan to have this done during the current study) Retinoid, microdermabrasion, or prescription-level glycolic acid treatments to the glabellar area within 2 weeks prior to study participation or during the current study. Concurrent therapy that, in the investigator's opinion, would interfere with evaluation

2012 Clinical Trials

146. Revlite Laser System Compared to the Candela Alex TriVantage System Refractory Mixed Type Melasma

microdermabrasion in past 3 months, other laser or Intense Pulsed Light treatment or chemical peels to the face in past 6 months, injectable fillers, topical retinoids, over-the-counter anti-aging products past 2 weeks. Has a history of keloids or hypertrophic scarring Has permanent make-up and/or is unwilling to refrain from using semi-permanent cosmetics during study Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact

2012 Clinical Trials

147. Effect of a Transcutaneous Electrical Nerve Stimulation (TENS) Device on Overall Facial Appearance

of the study Subjects who agree not to have any other procedures affecting skin quality (microdermabrasion, resurfacing, peels, lasers, acne treatments, etc.) for the duration of the study Subjects who agree to make no changes in their existing skincare regime during the study period Subjects who agree to avoid excessive sun radiation or use appropriate sun protection with SPF 30 or higher Subjects who agree not to alter their diet for the duration of the study Subjects who understand this study

2012 Clinical Trials

148. Feasibility Study: Heavy Water Tissue Labeling Protocol

of any study-related procedure. Exclusion Criteria: Presence of an active systemic or local skin disease that may affect wound healing. Severe solar elastosis. Significant scarring in areas to be treated. Open wounds or lesions in the area to be treated. Severe or cystic acne on the area to be treated. Presence of a metal stent or implant in the facial area to be treated. Inability to understand the protocol or to give informed consent. Microdermabrasion, or prescription level glycolic acid

2012 Clinical Trials

149. U0289-402: An Open Label, 8 Week Study to Evaluate the Efficacy and Tolerability of MAXCLARITY II in Subjects With Acne

cancer treatment in preceding 12 months. Has damaged skin on facial areas (eg, sunburn, tattoo, or scar) Had any medical procedure (eg, laser resurfacing, chemical peel, or plastic surgery) on facial areas in preceding 12 months. Had any cosmetic procedure (eg, microdermabrasion) on facial areas within 8 weeks of the baseline visit. Has any dermatological disorder that in the opinion of the investigator may interfere with the accurate evaluation of the subject's facial appearance. Received any

2012 Clinical Trials

150. U0289-401: Eight Week, Split-face, Study to Determine and Compare the Efficacy and Tolerability of MAXCLARITYâ„¢ II to PROACTIVâ„¢

of acute or chronic disease that might interfere with or increase the risk of study participation. Had skin cancer treatment in preceding 12 months. Has damaged skin on facial areas (eg, sunburn, tattoo, or scar) Had any medical procedure (eg, laser resurfacing, chemical peel, or plastic surgery) on facial areas in preceding 12 months. Had any cosmetic procedure (eg, microdermabrasion) on facial areas within 8 weeks of the baseline visit. Has any dermatological disorder that in the opinion

2012 Clinical Trials

151. Feasibility Study: Evaluation of Ulthera Versus Thermage for Treating the Face and Neck

on the area(s) to be treated. Presence of a metal stent or implant in the area(s) to be treated. Inability to understand the protocol or to give informed consent. Microdermabrasion, or prescription level glycolic acid treatment to the treatment area(s) within two weeks prior to study participation or during the study. Marked asymmetry, ptosis, excessive dermatochalasis, deep dermal scarring, or thick sebaceous skin in the area(s) to be treated. BMI equal to or greater than 25. Contacts and Locations Go

2012 Clinical Trials

152. Evaluation of the Ulthera System for the Treatment of the Decolletage

in the areas to be treated. Patients with ports or defibrillators. Any open wounds or lesions in the area. Active and severe inflammatory acne in the region to be treated. Patients who have a history with keloid formation or hypertrophic scarring. Inability to understand the protocol or to give informed consent. Retinoid, microdermabrasion, or prescription level glycolic acid treatments to the décolletage area within two weeks prior to study participation or during the study. Marked décolletage asymmetry

2012 Clinical Trials

153. Advanced Treatment Modalities for Vitiligo. (Abstract)

pharmacologic treatments. These advanced interventions include the use of the 308-nm excimer laser, total body depigmentation therapy with monobenzyl ether of hydroquinone, microdermabrasion, micropigmentation, khellin-UVA therapy, and surgical management using miniature punch grafting, suction blister grafting, and epidermal cultures.This article reviews the current literature on these advanced treatment modalities for vitiligo and provides a practical guide for application of these techniques.Our ability

2012 Dermatologic Surgery

154. Feasibility Study: Ulthera System for the Treatment of Rosacea

hyperpigmentation. Papulopustular or Phymatous Rosacea. Severe solar elastosis. Significant scarring in area(s) to be treated. Open wounds or lesions in the area(s) to be treated. Severe or cystic acne on the area(s) to be treated. Presence of a metal stent or implant in the area(s) to be treated. Inability to understand the protocol or to give informed consent. Microdermabrasion, or prescription level glycolic acid treatments to the intended treatment area(s) within six weeks prior to study participation

2012 Clinical Trials

155. Patient Satisfaction Study of BOTOX® Cosmetic in the Treatment of Moderate to Severe Frown Lines

using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years to 65 Years (Adult, Older Adult) Sexes Eligible for Study: Female Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Moderate to severe glabellar wrinkles (frown lines) Exclusion Criteria: Previous treatment with botulinum toxin therapy of any serotype Facial non-ablative resurfacing laser or light treatment, microdermabrasion, or superficial peels within 3

2011 Clinical Trials

156. Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Forehead and Frown Lines

serotype within one year Diagnosis of myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis Prior facial cosmetic surgery (e.g. prior periorbital surgery, facial lift, brow lift, eyelid lift or eyebrow surgery) Facial laser or light treatment, microdermabrasion, or superficial peels within 3 months Oral retinoid therapy within one year Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact

2011 Clinical Trials

157. Short-incubation Levulan Photodynamic Therapy Versus Vehicle for Face/Scalp Actinic Keratosis (AK)

[e.g.glycolic acid, lactic acid, etc. greater than 5%], salicylic acid (greater than 2%) within 2 days of initiation of treatment. Cryotherapy within 2 weeks of initiation of treatment Retinoids, including tazarotene, adapalene, tretinoin, retinol, within 4 weeks of initiation of treatment. Microdermabrasion, laser ablative treatments, ALA-PDT, chemical peels, 5-FU, diclofenac, imiquimod or other topical treatments for AK within 8 weeks of initiation of treatment. Two or more ALA PDT treatments in the past

2011 Clinical Trials

158. Safety and Efficacy of Single Therapy Versus Double and Triple Therapy of the Pellevé™ Wrinkle Treatment System for the Treatment of Moderate Facial Wrinkles

scars that may affect evaluation of response and/or quality of photography. Ablative skin resurfacing on the glabellar area within the previous 6 months or during the study. Retinoid, microdermabrasion, or prescription level glycolic acid treatments within 3 months prior to study participation or during the study. Active cut, wound, or infection on the skin. Oral Isotretinon within the past 12 months. Active HSV-1. History of keloids or hypertrophic scarring. Existing or history of skin malignancy

2011 Clinical Trials

159. Prospective Pellevé™ Neck Wrinkle Study

enrollment through the duration of the study. Subjects who have had a prior cosmetic procedure to improve rhytids in the treatment area (i.e.,rhytidectomy, CO2/erbium laser resurfacing, Thermage/Thermacool radiofrequency treatment)within 12 months or who have visible scars that may affect evaluation of response and/or quality of photography. Microdermabrasion, or prescription level glycolic acid treatments within 3 months prior to study participation or during the study. Active cut, wound, or infection

2011 Clinical Trials

160. U0289-405: An Open-Label, 12-Week Study to Evaluate the Efficacy and Safety of the Acne System (Benzoyl Peroxide 2.5%, Salicylic Acid 0.5%) in Subjects With Acne

, anti-wrinkle, antimicrobials, glycolic acid, abradants) within the past 2 weeks. Use of superficial facial procedures, and natural/herbal products within the past 4 weeks. Concomitant use of medications that are reported to exacerbate acne as these may impact efficacy assessments. Facial procedure (eg, blue light, chemical or laser peel, microdermabrasion) performed by aesthetician, beautician, physician, nurse, or other practitioner within the past 8 weeks. facial skin cancer diagnosis

2011 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>